This activity is jointly sponsored/co-provided by Postgraduate Institute for Medicine and CMEology.
This activity is supported by an educational grant from Baxter Healthcare.
Release date: December 31, 2013
Valid through: January 31, 2015
This activity has been designed to meet the educational needs of physicians, registered nurses, nurse practitioners, pharmacists, and social workers involved in the care of patients with bleeding disorders.
Hemophilia B, a genetic deficiency of coagulation factor IX, is a chronic and potentially debilitating disease that negatively impacts patients' quality of life. On-demand use of plasma-derived or recombinant factor IX (rFIX) for episodic bleeding remains the mainstay of treatment, despite evidence that long-term prophylaxis with rFIX is the optimal strategy to decrease bleeding episodes and prevent disability. Consistent, regular treatment with long-term prophylaxis is key to successfully preventing bleeding episodes, but many practitioners lack strategies to address adherence problems among their patients with hemophilia B. Healthcare practitioners usually have more experience managing hemophilia A, and they may be unaware of new and emerging therapies that offer additional or improved options for their patients affected by hemophilia B.
It is important to educate those who treat hemophilia patients on comprehensive, multidisciplinary care using the latest treatment strategies for hemophilia B, especially given its relatively uncommon occurrence compared with hemophilia A and the lack of information in the literature. In this activity, expert faculty will provide an update on the therapeutic goals and treatment options for hemophilia B, discuss the rationale for and data supporting prophylaxis as a best practice, and present methods to measure and successfully impact adherence to treatment and quality of life for patients with hemophilia.